Login to Your Account



Raise the 'Curtana' for start-up with $7.6M grant for GBM therapy

By Marie Powers
Staff Writer

Thursday, August 21, 2014
A year after its official launch, Curtana Pharmaceuticals Inc. stepped onstage holding a $7.6 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to fund its lead cancer therapy program, which is targeting the OLIG2 transcription factor (TF) – initially in glioblastoma multiforme (GBM).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription